Hiroyuki Okuzawa succeeds Sunao Manabe as Daiichi Sankyo CEO
Daiichi Sankyo has announced that Hiroyuki Okuzawa will succeed Sunao Manabe as its CEO from 1 April 2025. The company's board …
Post
-
-
FDA approves Vertex’s acute pain treatment Journavx
The US Food and Drug Administration (FDA) has approved Vertex Pharmaceuticals’ oral Journavx (suzetrigine) to treat adults with acute pain. The …
-
RFK Jr. thrusts domestic manufacturing agenda on Day 2 of confirmation hearings
Robert F. Kennedy Jr. (RFK Jr) has claimed that “China will be able to ransom medical health” in America due …
-
MHRA launches refreshed ILAP to speed up NHS drug access
The UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has launched a refreshed Innovative Licensing and Access Pathway (ILAP) to …
-
Takeda announces appointment of Julie Kim as CEO
Takeda has announced the appointment of Julie Kim as successor to Christophe Weber, its current president, CEO and representative director, …
-
Leveragen and Moonlight Bio unite for T-cell therapy development
Leveragen has announced a strategic partnership with Moonlight Bio, targeting the development of T-cell therapies for challenging cancers. The partnership integrates …
-
Acellera and Psivant partner for AI-driven drug discovery
Acellera Therapeutics and Psivant Therapeutics have announced a strategic research partnership aimed at developing computational drug discovery approaches with the …
-
Lyndra Therapeutics appoints Adam Sayer new CEO and president
Lyndra Therapeutics has announced the immediate appointment of Adam Sayer as its new president and CEO. Sayer, who will also join …
-
FDA expands Enhertu approval to include HER2-ultralow breast cancer patients
AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) has received approval from the US Food and Drug Administration …
-
Lantheus acquires radiopharma CDMO Evergreen for up to $1bn
US-based radiopharmaceutical company Lantheus has announced a definitive agreement to acquire clinical-stage radiopharma contract development and manufacturing organisation (CDMO) Evergreen …
-
Novo Nordisk secures FDA approval for Ozempic in diabetes with CKD
The US Food and Drug Administration (FDA) has approved Novo Nordisk’s Ozempic (semaglutide) to reduce certain risks associated with chronic …
-
Sonnet BioTherapeutics secures EU patent for FHAB technology
Sonnet BioTherapeutics has received a patent from the European Patent Office (EPO) for its fully human albumin binding (FHAB) technology. The …
-
Will European PFAS ban disrupt pharma supply chains?
Used in consumer products since the 1950s, perfluoroalkyl and polyfluoroalkyl substances (PFAS) are synthetic chemicals with strong fluorine-carbon bonds, earning …
-
FDA gives RMAT designation to Beacon’s retinitis pigmentosa treatment
The US Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to Beacon Therapeutics’ gene therapy, …
-
Allakos cuts 75% of workforce after chronic hives trial failure
Allakos has announced a 75% workforce reduction and the discontinuation of its chronic spontaneous urticaria (CSU) AK006 development programme following …
